IR@PKUHSC  > 北京大学第一临床医学院  > 感染疾病科
学科主题感染疾病科
HBeAg阳性慢性乙型肝炎患者拉米夫定及其与普通干扰素序贯治疗效果比较
其他题名Lamivudine-interferon alpha 2b sequential therapy versus lamivudine monotherapy in HBeAg-positive chronic hepatitis B patients
徐京杭1; 于岩岩1; 斯崇文1; 陈新月1; 韩忠厚1; 陈勇1; 张文瑾1; 徐道振1; 陈宇萍1; 李雪迎1; 仇杰1
关键词肝炎 干扰素α-2b 乙型 肝炎e抗原 拉米夫定 慢性 乙型 变异(遗传学) Hepatitis b e Antigens Hepatitis b Interferon Alfa-2b Chronic Lamivudine Variation (Genetics)
刊名中华传染病杂志
2012
DOI10.3760/cma.j.issn.1000-6680.2012.06.008
30期:6页:354-358
收录类别中国科技核心期刊 ; 中文核心期刊 ; CSCD
文章类型Journal Article
摘要目的 比较拉米夫定-干扰素序贯治疗与拉米夫定单药治疗HBeAg阳性慢性乙型肝炎患者的疗效和安全性.方法 选择172例HBeAg阳性慢性乙型肝炎患者,随机分为序贯治疗组83例和拉米夫定单药治疗组89例.序贯治疗组先用拉米夫定100mg/d治疗,从第25周开始加用干扰素α2b(5MU,皮下注射,隔日1次),总疗程48周,停药后随访24周.单药治疗组单用拉米夫定100mg/d治疗,共48周,停药后随访24周.计量资料方差齐性用t检验,方差不齐用秩和检验,率的比较用x2检验或Fisher确切概率法.结果 序贯治疗组和单药治疗组的基线HBV DNA分别为(7.8±1.0)和(7.9±1.1)1g拷贝/mL(P>0.05),基线ALT分别为(210.5±150.1)和(211.9±160.9)U/L(P>0.05).治疗结束时,序贯治疗组ALT为(78.4±146.1)U/L,单药治疗组ALT为(36.1±32.4)U/L,两组比较,差异有统计学意义(P<0.05);序贯治疗组HBV DNA为(4.5±1.5)1g拷贝/mL,单药治疗组HBV DNA为(3.8±1.3)1g拷贝/mL(P<0.05);应答率分别为65.8%、83.5%(P<0.05);HBeAg阴转率分别为31.6%、22.2%(P>0.05);血清学转换率分别为27.6%、16.0%(P>0.05).随访结束时,序贯治疗组ALT为(126.0±143.1)U/L,单药治疗组ALT为(82.7±83.0)U/L,两组比较,差异有统计学意义(P<0.05);序贯治疗组HBV DNA为(5.3±1.5)1g拷贝/mL,单药治疗组HBV DNA为(5.0±1.5)1g拷贝/mL,两组比较,差异无统计学意义(P>0.05);HBeAg阴转率分别为25.0%、32.3%(P>0.05);血清学转换率分别为25.0%、26.2%(P>0.05).治疗48周时YMDD耐药变异率序贯治疗组低于单药治疗组(10.5%比26.9%,P<0.05).结论 拉米夫定-干扰素序贯治疗和拉米夫定单药治疗对HBeAg阳性慢性乙型肝炎患者疗效相似,但序贯治疗可减少病毒变异. Objective To compare the efficacy and safety of Iamivudine-interferon sequential therapy and lamivudine monotherapy in HBeAg-positive chronic hepatitis B (CHB) patients.Methods A total of 172 patients with HBeAg-positive CHB were randomized to sequential group (n=83) or lamivudine group (n=89).Sequential group were administrated with lamivudine 100 mg/d and 5 million units interferon alpha 2b subcutaneous injection every other day for 24 weeks were added since week 25 of treatment.Lamivudine group were administrated with lamivudine 100 mg/d for 48 weeks.All subjects were followed up for 24 weeks after drug withdrawal.Measurement data with homogeneity of variance were analyzed by using t test and data with heterogeneity of variance were analyzed by using rank sum test.The comparison of rates was done by chi square test or Fisher exact test.Results The baseline hepatitis B virus (HBV) DNA levels of patients in sequential group and lamivudine group were (7.8±1.0) and (7.9±1.1) lg copy/mL,respectively (P>0.05),and the baseline alanine aminotransferase (ALT) levels were (210.5 ± 150.1 ) and (211.9 ± 160.9) U/L,respectively (P>0.05).At the end of treatment,higher ALT levels [(78.4±146.1) vs (36.1±32.4) U/L,P<0.05)] and HBV DNA levels [(4.5±1.5) vs (3.8±1.3) lg copy/mL,P<0.05)] levels,lower response rates (65.8% vs 83.5%,P<0.05),and similar HBeAg loss rates (31.6% vs 22.2%,P>0.05) and HBeAg seroconversion rates (27.6% vs 16.0%,P>0.05) were found in sequential group compared with lamivudine group.At the end of follow-up,higher ALT levels [(126.0±143.1) vs (82.7±83.0) U/L,P<0.05)],similar HBV DNA levels [(5.3±1.5) vs (5.0±1.5) lg copy/mL,P>0.05)],similar HBeAg loss rates (25.0% vs 32.3%,P>0.05) and HBeAg seroconversion rates (25.0 % vs 26.2 %,P>0.05) were found in sequential group compared with lamivudine group.YMDD motif mutation rate in sequential group was lower than lamivudine group at week 48 of treatment (10.5% vs 26.9%,P<0.05).Conclusions Lamivudine-interferon sequential therapy and lamivudine monotherapy are both effective in HBeAg-positive CHB patients,while HBV mutations are reduced in patients with sequential therapy.
语种中文
原文出处查看原文
Citation statistics
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/41877
Collection北京大学第一临床医学院_感染疾病科
作者单位1.100034,北京大学第一医院感染疾病科
2.首都医科大学附属北京佑安医院国际医疗部
3.河北省秦皇岛市第三医院感染科
4.江苏省淮安市第四人民医院肝病研究所
5.解放军第三○二医院军人肝病诊疗中心
6.首都医科大学北京地坛医院肝病科
7.河北省保定市传染病医院肝病研究所
8.100034,北京大学第一医院医学统计室
9.甘肃省妇幼保健院感染科
Recommended Citation
GB/T 7714
徐京杭,于岩岩,斯崇文,等. HBeAg阳性慢性乙型肝炎患者拉米夫定及其与普通干扰素序贯治疗效果比较[J]. 中华传染病杂志,2012,30(6):354-358.
APA 徐京杭.,于岩岩.,斯崇文.,陈新月.,韩忠厚.,...&仇杰.(2012).HBeAg阳性慢性乙型肝炎患者拉米夫定及其与普通干扰素序贯治疗效果比较.中华传染病杂志,30(6),354-358.
MLA 徐京杭,et al."HBeAg阳性慢性乙型肝炎患者拉米夫定及其与普通干扰素序贯治疗效果比较".中华传染病杂志 30.6(2012):354-358.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[徐京杭]'s Articles
[于岩岩]'s Articles
[斯崇文]'s Articles
百度学术
百度学术Similar articles in
[徐京杭]'s Articles
[于岩岩]'s Articles
[斯崇文]'s Articles
必应学术
必应学术Similar articles in
[徐京杭]'s Articles
[于岩岩]'s Articles
[斯崇文]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.